The potential role of lycopene for the prevention and therapy of prostate cancer: From molecular mechanisms to clinical evidence by Holzapfel, Nina Pauline et al.
This is the author’s version of a work that was submitted/accepted for pub-
lication in the following source:
Holzapfel, Nina Pauline, Holzapfel, Boris Michael, Champ, Simon,
Feldthusen, Jesper, Clements, Judith A., & Hutmacher, Dietmar Werner
(2013) The potential role of lycopene for the prevention and therapy of
prostate cancer : from molecular mechanisms to clinical evidence. Inter-
national Journal of Molecular Sciences, 14(7), pp. 14620-14646.
This file was downloaded from: http://eprints.qut.edu.au/66485/
c© Copyright 2013 by the authors; licensee MDPI, Basel, Switzerland
This article is an open access article distributed under the terms
and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/3.0/).
Notice: Changes introduced as a result of publishing processes such as
copy-editing and formatting may not be reflected in this document. For a
definitive version of this work, please refer to the published source:
http://dx.doi.org/10.3390/ijms140714620
Int. J. Mol. Sci. 2013, 14, 14620-14646; doi:10.3390/ijms140714620 
 
International Journal of 
Molecular Sciences 
ISSN 1422-0067 
www.mdpi.com/journal/ijms 
Review 
The Potential Role of Lycopene for the Prevention and  
Therapy of Prostate Cancer: From Molecular Mechanisms to  
Clinical Evidence 
Nina Pauline Holzapfel 
1
, Boris Michael Holzapfel 
1
, Simon Champ 
2
, Jesper Feldthusen 
2
,  
Judith Clements 
3
 and Dietmar Werner Hutmacher 
1,4,5,
* 
1
 Regenerative Medicine, Institute of Health and Biomedical Innovation,  
Queensland University of Technology, 60 Musk Avenue, Kelvin Grove,  
QLD 4059, Brisbane, Australia; E-Mails: ninapauline.holzapfel@qut.edu.au (N.P.H.);  
holzapfel@orthopaedic-oncology.net (B.M.H.) 
2
 Human Nutrition, BASF SE, G-ENH/MB, 68623 Lampertheim, Germany;  
E-Mails: simon.champ@basf.com (S.C.); jesper.feldthusen@basf.com (J.F.) 
3
 Australian Prostate Cancer Research Centre, Translational Research Institute, 37 Kent Street, 
Woolongabba, QLD 4102, Brisbane, Australia; E-Mail: j.clements@qut.edu.au  
4
 The George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology,  
801 Ferst Drive Northwest, Atlanta, GA 30332, USA 
5
 Institute of Advanced Study, Technical University of Munich, Lichtenbergstr. 2a, 85748 Garching, 
Munich, Germany 
* Author to whom correspondence should be addressed; E-Mail: dietmar.hutmacher@qut.edu.au;  
Tel.: +61-7-3138-6077; Fax: +61-7-3138-6030. 
Received: 17 May 2013; in revised form: 29 May 2013 / Accepted: 20 June 2013 /  
Published: 12 July 2013 
 
Abstract: Lycopene is a phytochemical that belongs to a group of pigments known as 
carotenoids. It is red, lipophilic and naturally occurring in many fruits and vegetables, with 
tomatoes and tomato-based products containing the highest concentrations of bioavailable 
lycopene. Several epidemiological studies have linked increased lycopene consumption 
with decreased prostate cancer risk. These findings are supported by in vitro and in vivo 
experiments showing that lycopene not only enhances the antioxidant response of prostate 
cells, but that it is even able to inhibit proliferation, induce apoptosis and decrease the 
metastatic capacity of prostate cancer cells. However, there is still no clearly proven 
clinical evidence supporting the use of lycopene in the prevention or treatment of prostate 
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cancer, due to the only limited number of published randomized clinical trials and the 
varying quality of existing studies. The scope of this article is to discuss the potential 
impact of lycopene on prostate cancer by giving an overview about its molecular 
mechanisms and clinical effects.  
Keywords: lycopene; prostate cancer; disease prevention; treatment; molecular 
mechanisms; animal models 
 
1. Introduction 
Prostate cancer is the second most frequently diagnosed cancer worldwide among men. Incidence 
rates are highest in Australia, Western Europe and Northern America, whereas the lowest incidence 
rate is found in South-Central Asia. In 2008, prostate cancer was the sixth leading cause of death from 
cancer among men worldwide. Prostate specific antigen (PSA) testing has been shown to have a 
greater influence on incidence than on mortality [1]. Therefore, there is a larger variety in incidence 
rates than in mortality rates. Interestingly, the number of deaths in developing countries is not 
excessively different from more affluent countries [2]. This fact generated a discussion in the field 
about the benefit of early detection and aggressive treatment of early localized prostate cancer [3]. 
While in many cases, there is still uncertainty about the time of initiation and the radicalness of the 
therapy, the field agrees about the need for effective preventive measurements of the disease [4].  
In the last decade, an increasing amount of scientific information has been published about the 
potential to prevent diseases by complementary and alternative medicine [5]. These studies might 
influence people’s attitude towards the use of dietary supplements, but there is also a rising interest of 
consumers in their own healthcare [6]. These so-called ―community-based lifestyle interventions‖ are 
envisioned to improve general health, boost the immune system and even provide a cure for cancer. 
Recent studies have shown that prostate cancer patients are particularly attracted by complementary or 
alternative medicine products [7,8]. This is easy to understand when one is made aware of the fact that 
incidence rates of prostate cancer vary by more than 25-fold worldwide [2], suggesting that 
environmental or dietary factors might play a role in the development of prostate cancer [9]. The 
prevalence of using complementary and alternative therapeutic methods among patients with prostate 
cancer has been shown to be around 30% [7], and approximately 25% use herbs, minerals, vitamins 
and antioxidants, such as green tea, selenium, vitamin E or lycopene [10]. Patients with advanced 
forms of the disease and those treated with hormones are even more susceptible to use these products [8]. 
The interest on lycopene rich diets and supplements for the prevention or therapy of prostate cancer 
has extremely increased during the last years. Lycopene products are well tolerated and meet the 
requirements of the US Food and Drug Administration for the designation of Generally Recognized as 
Safe (GRAS). However, it is still questionable if there is a definitive evidence to recommend it to 
patients in addition to a well-balanced diet. The aim of this review is to give an up-to-date overview 
about the properties of lycopene, its molecular and cellular mechanisms with special regard to the 
actual clinical evidence for its use in the prevention and therapy of prostate cancer. 
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2. Chemical Properties of Lycopene 
More than 600 carotenoids are known to be naturally occurring. These predominantly colourful 
molecules, built by plants, fungi and bacteria undergoing photosynthesis, are widespread in vegetables 
and fruits [11,12]. Carotenoids are divided into two main groups. Of them, highly unsaturated 
hydrocarbons consisting of lycopene, α-, β-, and γ-carotene build the first group, whereas 
xanthophylls, such as β-cryptoxanthin, lutein, and zeaxanthin, are considered as the second big 
carotenoid-group. The first class, hydrocarbon carotenoids, contains only carbon- and hydrogen-atoms, 
but lack oxygen, whereas xanthophylls, in contrast, consist of at least one oxygenated group on their 
terminal rings [12]. Even though all carotenoids exhibit certain joint chemical features, like a distinct 
conjugated double bond system, a polyisoprenoid structure and an almost bilateral symmetry around 
the centrical situated double-bond, modifications of the main structure, like cyclization of terminal 
groups and insertion of oxygen functions, lead to different types of carotenoids with varying 
characteristic colours and antioxidant qualities [13,14].  
Lycopene, a representative of the hydrocarbon carotenoids with the molecular formula of C40H56, has 
an acyclic open-chain structure consisting of 13 double-bonds. Two of them are non-conjugated, whereas 
eleven are conjugated double bonds, thereby building a chromatophore [12]. This distinctive conjugated 
polyene structure accounts for the ruby colour and the antioxidant properties of lycopene [12]. It has a 
distinct lipophilic character, which makes it nearly insoluble in ethanol, methanol and water [15]. Due 
to its acyclic structure and the absence of a β-ionone ring, there is no pro-vitamin A activity to be 
found in lycopene, which is the reason for its differing biochemistry, as compared to α- and  
β- carotene [15]. The prevalent biological occurring form of lycopene is the all-trans-isomer, which is 
also the thermodynamically most stable configuration [16]. Indeed, heat, light or several chemical 
reactions can induce isomerization from the trans-isomer to various mono- or poly-cis forms [12]. The 
lycopene forms detected in human serum and tissues range from all-trans to 9-, 13- and 15-cis isomers, 
whereas the predominant naturally occurring configuration in food is the all-trans form (Figure 1). 
Hence, it is expected that in vivo isomerization mechanisms exist [17]. 
Figure 1. All-trans-lycopene and its metabolites, 5-cis, 9-cis, 13-cis and 15-cis-lycopene. 
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2.1. Anti-Oxidant Properties 
Due to its polyene-structure, providing an electron-rich system, lycopene is an eligible target for 
electrophilic reagents. Thus, it performs an uttermost reactivity towards oxygen and free radicals [18]. 
Lycopene is known to be the most potent oxygen quenching reagent among carotenoids, and 
furthermore, it provides the ability to intervene in reactions initiated by free radicals, like OH
−ˑ
 or 
peroxy radicals [18,19]. Its excellent anti-oxidant properties are most likely the basis for its preventive 
role towards cancer and other chronic diseases. 
The ability to quench oxygen increases with the opening of the β-ionone ring in the molecule 
structure, as found by direct comparison of lycopene, γ-carotene and β-carotene. This might be the 
result of the lowering of the energy level, which provides the ability to approach a triplet energy level. 
From this stage, the energy transfer from the excited state of oxygen can be adopted easily [19].  
As lycopene exhibits the greatest potential in oxygen quenching among all carotenoids, its isomers 
have been found to vary in their antioxidant properties, as well. 5-cis lycopene has been found  
to be most potent, followed by 9-cis. The weakest antioxidant properties have been reported for the  
all-trans isomer [20].  
Carotenoids or lycopene, respectively, act as antioxidants through several mechanisms. Highly 
reactive oxygen species, also named singlet oxygen (
1
O2), which are able to oxidize nucleic acids, 
unsaturated fatty acids or amino acids, can be quenched by carotenoids/lycopene exerting the reaction 
stated below [18]:  
1
O2 + LYC → 
3
O2 + 
3
LYC 
3
LYC → LYC + heat 
The exceeding amount of energy, the lycopene molecule gained in this reaction reaching the triplet 
state, is dispensed through vibrational, as well as rotatory interactions with the solvent, resulting in the 
release of thermal energy. Once more, the extensive conjugated polyene structure of lycopene is 
responsible for this reaction. As the molecule re-establishes its ground state immediately, another 
1
O2 
quenching cycle can be activated, thereby providing the possibility of each single carotenoid-molecule 
to quench about 1000 molecules of 
1
O2 [18]. 
Lycopene and other carotenoids are also known for their antioxidant activities towards impeding 
free radical reactions. Peroxyl radicals are built in the organism during the process of lipid 
peroxidation, which can lead to destruction of lipophilic sections. Inactivation of these reactive species 
results in the development of radical adducts that build a resonance-stabilized carbon-centred radical. 
The carotenoid oxidation products include formation of epoxides located at the β-ionone ring, as well 
as located at the central double bond of the conjugated polyene chain. More products of this reaction 
are the formation of ketones and aldehydes at the β-ionone ring [21]. Inhibition of these radical 
reactions by lycopene may shelter membranes from lipid peroxidation [22]. 
Furthermore, lycopene is in discussion to be able to repair vitamin E and C radicals in vivo by 
conducting the following reaction [23]: 
LYC + α-Tocopherol + H+ → LYC+ + α-Tocopherol-H 
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Besides its radical reactions, lycopene has also been shown to upregulate the so-called antioxidant 
response element (ARE). Cellular enzymes, like glutathione S-transferase, superoxide dismutase or 
quinone reductase, are activated by lycopene, resulting in another way of protecting cells against 
highly reactive oxygen species [15]. Linnewiel et al. reported that hydrophilic oxidation products of 
carotenoids, rather than the intact lipophilic carotenoid molecules, have been found to be responsible 
for the stimulation of the ARE system, detected in vitro using LNCaP and MCF-7 cells [24]. Oxidized 
lycopene derivatives, built due to the instability of these molecules, are present in tomatoes, as well as 
in human serum and tissues. However, these oxidative products have been found to be present in 
different human tissues only at a rather small amount as compared to the parent compound. The 
described oxidation is most likely a natural metabolism reaction in tomatoes or can also happen during 
heat-processing of tomato-rich foods. Furthermore, in vivo oxidation reactions in humans resulting in 
the development of lycopene epoxides are discussed in the literature [25]. However, the contribution of 
these lycopene derivatives as active antioxidant compounds might be insignificant in vivo, due to the 
predominance of the intact lycopene molecule in most human tissues. 
2.2. Lycopene-Content in Different Sources 
Natural sources of lycopene include inter alia watermelon, rosehips, pink grapefruit, guava, 
apricots and, above all, tomatoes (Table 1).  
Table 1. Lycopene content of common fruits and vegetables [16,26,27]. 
Lycopene content [mg/100 g wet basis] Source 
0.7–20 Fresh tomatoes 
3.7 Cooked tomatoes 
2.3–7.2 Fresh watermelon 
2.0–5.3 Fresh papaya 
5.2–5.5 Pink guava 
0.4–3.4 Pink grapefruit 
0.01–0.05 Apricot 
As all tomato products contain high concentrations of lycopene, they are, at the same time, the most 
important source of this carotenoid for humans, accounting for over 85% of all dietary sources [26]. 
However, the lycopene concentration in fresh fruits shows a great variability, depending on 
environmental conditions, geographic location, climatic situation, species and maturity, but with an 
average of about 5 to 10 mg lycopene per 100 g tomato [12,28]. Up to 15 mg lycopene in 100 g fruit 
has been found for deep-red tomato varieties, whereas yellow species are less rich in lycopene, with a 
content of only about 0.5 mg per 100 g [28].  
Attempts to compare lycopene contents between organic grown tomatoes and conventionally grown 
ones emerged to be not consistent. Rossi et al. and Hallmann et al. found higher contents of lycopene 
in conventionally grown fruits [29,30], whereas Caris-Veyrat et al., on the contrary, discovered the 
opposite. They found a significantly higher amount of lycopene in organic grown tomatoes [31]. These 
differences could be appropriate to the findings of Ordonez-Santos et al. reported in 2011. They didn’t 
find statistically significant differences between organic and conventionally grown tomatoes, but 
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reported that the main factor affecting the micronutrient content of tomatoes might be the cultivar, 
rather than the cultivation method [32].  
Processed and, therefore, less hydrated tomato-products have been found to be richer in lycopene than 
whole, raw tomatoes. Tonucci et al., for example, examined the lycopene content of different tomato-based 
foods, like whole tomatoes, ketchup, spaghetti sauce, tomato paste, tomato puree and tomato sauce, 
thereby finding great differences between the raw fruit and processed products (Table 2) [33]. 
Table 2. Lycopene content of various tomato products (according to Tonucci et al. [33]). 
Lycopene content (mg/100 g) ± SD Source 
9.27 ± 1.02 Raw tomatoes 
17.23 ± 2.18 Ketchup 
15.99 ± 0.90 Spaghetti sauce 
55.45 ± 4.33 Tomato paste 
16.67 Tomato puree 
17.98 ± 1.47 Tomato sauce 
2.3. Bioavailability and Metabolism of Lycopene 
Absorption of lycopene from dietary sources occurs within the range of 10 to 30% in humans [34]. 
After ingestion, lycopene is taken up by dietary lipid micelles and incorporated into the mucosa of the 
small intestine. The micelles are packaged into chylomicrons, which are then transported to the liver 
using the lymph system. Lipoproteins carry the lycopene molecules into the plasma, from where they 
are distributed to their target organs [35]. Maximal concentrations have been found in the testes, 
prostate, adrenal glands and liver [36]. 
Many lifestyle factors, like smoking, consumption of alcohol, blood lipid levels, and also biological 
factors, such as age or hormonal status, have an influence on the absorption of lycopene [36]. Studies 
have also shown that absorption from processed tomato products is better than from raw tomatoes. 
Stahl et al. found an increase in the level of serum lycopene in humans only after consumption of 
processed juice, but not after administering unprocessed tomato juice [34]. Gaertner et al.  
compared tomato paste with fresh tomato salad, thereby finding a twofold increase of lycopene in 
serum after consumption of the paste [37]. As the bond between lycopene and macromolecules within 
the food-matrix is comparatively strong, its bioavailability from dietary sources is rather remote, but 
can be enhanced by processing the food, like cooking or chopping, in order to separate complexes 
between lycopene and protein [12,38]. The food matrix, to which lycopene is tightly attached, is 
thought to contribute to the maintenance of a stable all-trans isomer, thereby preventing the molecule 
to isomerize to the cis-conformation. By disrupting membranes of chromoplasts and reducing the 
integrity of cells, thermal and mechanical treatment may cause an easier release of lycopene from its 
surrounding matrix. The unbound molecule is now accessible for isomerisation into the  
cis-conformation, which is in discussion to improve the bioavailability [12,38]. Due to its lipophilic 
character, the addition of lipids to lycopene-containing foods can enhance the bioavailability,  
as well [39]. 
In most food sources, lycopene exists predominantly in the all-trans conformation. In contrast to 
this finding, the predominant isomeric form found in human and animal tissues—More precisely,  
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>50% of total lycopene, is the cis-isomer [17]. One of the reasons for this difference is that the  
cis-isomer is thought to provide a better bioavailability and that it might be more easily absorbed. Its 
solubility in the bile acid micelles is enhanced, due to a slightly changed structure, which makes the 
molecule shorter and, at the same time, more suitable to fit into the micelle [40,41]. All-trans isomers 
have been found to exhibit a greater disposition to aggregate in the intestine, thereby building crystals, 
which may reduce their uptake through micelles [14]. Other studies investigating the bioavailability of 
lycopene indicated that possible isomerisation procedures in the stomach could be the answer for the 
enhanced presence of cis-lycopene in human tissues, as compared to trans-lycopene [42,43].  
Re et al. [42], for example, incubated lycopene from dietary supplement capsules or, alternatively, 
tomato puree with human or simulated gastric juice to detect the percentage of isomerisation. The 
amount of cis-isomers increased for both sample-types after treatment with gastric juice, but the 
dietary capsules showed a higher percentage in the cis-stereoisomeric form, which might be an 
indicator for the stabilizing effect of the plant matrix. Isomerisation was furthermore dependant on the 
pH level, as it was enhanced when the pH was below 2 and as it remained static when the pH was 
adjusted to ~7. Following these findings, the most supposable reason of cis-isomer formation might be 
the existence of an acidic environment in the stomach [42]. As the findings of lycopene bioavailability 
and absorption are still not entirely clear, there are more investigations required to detect and 
understand the pathways of its metabolism [44]. 
Due to a consistently increasing market for dietary supplements, studies have been conducted, 
investigating the bioavailability of synthetic lycopene as compared to naturally derived, unprocessed or 
processed lycopene. For this purpose, Hoppe et al. [45] used two different Lycopene beadlet 
formulations, which have been administered to 36 healthy volunteers over a period of 28 days: 
LycoVit™ 10% (BASF, Ludwigshafen, Germany, synthetic lycopene) and Lyc-O-Mato™ beads 5% 
(LycoRed Natural Products Industries Ltd, naturally derived lycopene). Lyc-O-Mato™ is a  
tomato-oleoresin, extracted from tomatoes. It contains lycopene and other phytonutrients, such as 
tocopherols, phytoene, phytofluene, β-carotene, phospholipids and phytosterols. The findings of this 
study resulted in a precise and similar increase of total, as well as cis- and trans-lycopene serum 
response for both sources, thereby indicating an equivalent bioavailability of synthetic and  
naturally-derived lycopene [45].  
Cohn et al. [46] compared plasma kinetics after administering synthetic lycopene (5 mg lycopene 
tablets, 5%), a processed natural lycopene source (tomato soup from tomato paste) and an unprocessed 
natural source (tomato juice). In this study, the absorption of the synthetic formulation was comparable 
to the processed product, but enhanced as compared to the unprocessed tomato juice. This 
demonstrates again the importance of processing food to enhance the bioavailability of lycopene [46]. 
Results from a study performed by Tang et al. [47] demonstrate even a predominance in the 
bioavailability for synthetic lycopene as compared to the natural carotenoid from steamed-pureed 
tomatoes, as they found almost three-times higher lycopene-absorption in human probands of the 
synthesized product than for the natural one. The tomato matrix, as well as the preparation-procedure, 
which didn’t include heating in oil, might be responsible for this inferior outcome of the  
natural source [47].  
The results of these findings might be of great interest, particularly for elderly and multi-morbid 
people, as their ingestion can be reduced or disturbed. Lycopene intake in the form of a supplement 
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could most likely provide a more convenient way of benefitting from its potential antioxidant and  
anti-cancer properties for those patients than consuming lycopene-rich food. The potential properties 
of lycopene to target cancer cells will be discussed in the following sections. 
3. Molecular Mechanisms of Lycopene on Prostate Cancer Cells: In Vitro Models 
One of the possible reasons leading to prostate cancer development includes a series of mutations in 
genes controlling cell differentiation and growth. A chronic inflammation process in bacterial 
prostatitis, for example, can lead to the production of reactive oxygen species (ROS). This might 
contribute to oxidative damage of DNA, resulting in gene mutations. Exogenous carcinogens can have 
similar effects. DNA defects are usually detected by the cell surveillance system, which initializes cell 
cycle arrest to re-establish DNA integrity. If the DNA damage is irreparable, the consequence will be 
apoptosis of the cell. However, malfunctioning repair mechanisms can initiate mutations, followed by 
potential cancer development [48]. 
3.1. Prevention of DNA Damage  
Androgen has been reported to induce an increase of ROS in prostate cancer cells [49]. Goo et al. 
investigated changes in protein-expression of androgen-depleted and androgen-sufficient LNCaP cells 
by conducting quantitative proteomic analysis [50]. After treatment with 0.2 µM lycopene, they found 
increased numbers of detoxification proteins, such as epoxide hydrolase-1, which is involved in the 
hydrolysis of epoxides to transfer these proteins to less reactive species. Furthermore, the proteins, 
superoxide dismutase-1, which degrades radicals in cells, and catalase, which protects cells from 
hydrogen peroxide, have been found to be increased. This has also been detected for metal binding 
protein, transferrin, which binds to iron and prevents it from producing oxidative stress. Lycopene has 
been found to induce a moderate increase of these detoxification proteins in androgen-sufficient and a 
significant increase in androgen-depleted LNCaP cells. Though the amount of detected proteins has 
been low, it can be hypothesized that lycopene provides a protective mechanism in preventing DNA 
damage, due to an increased expression of these proteins [50]. Another study conducted by Qiu et al. 
in 2013 analysed protein expression by using iTRAQ proteomics after exposure of prostate epithelial 
cells to 2 µmol/L lycopene for 48 hours. Lycopene increased the amount of phase II protective 
enzymes, such as glutathione-S-transferase-omega-1, peroxiredoxin-1 and sulphide-quinone 
oxidoreductase. Proteins, such as ERO1-like protein-α or CLIC-1, usually involved in ROS generation, 
have been shown to be downregulated after treatment with lycopene. This indicates a potential of 
lycopene to lower the risk for the generation of ROS and to reduce oxidative stress [51].  
By using ferric nitrilotriacetate (FE-NTA) plus ascorbic acid, Matos et al. [52] induced oxidative 
damage to DNA in green monkey kidney fibroblasts (CV1-P), measured via the formation of  
8-hydroxydeoxyguanosine (8-OHdG), which has been shown to be a specific marker for oxidative 
DNA damage. The presence of 8-OHdG has been discussed to be associated with mutagenesis and 
carcinogenesis [53,54]. Addition of lycopene in a concentration of 20 pmol/10
6
 cells has been shown 
to decrease 8-OHdG levels in DNA by 77%, thereby indicating a protective effect of lycopene against 
oxidation of DNA in mammalian cells [52].  
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However, a study carried out by Hwang et al. [55], investigating the protective potential of 
lycopene towards oxidative DNA damage in LNCaP human prostate cancer cells, revealed not only 
failure in protection against oxidative DNA damage at physiological concentrations of lycopene  
(0.1–1 µM), but also a pro-oxidative effect at higher lycopene concentrations (>5 µM) [55]. This has 
also been shown by Lowe et al. [56] in a study using a HT29 colon carcinoma cell line. Low doses  
(1–3 µM) of lycopene or β-carotene protected DNA from damage induced by xanthine/xanthine 
oxidase. However, by increasing the concentrations (4–10 µM) of the test substances, the opposite 
effect has been observed [56]. 
Anti-oxidant and pro-oxidant qualities of lycopene under cell culture conditions seem to change in a 
time- and dose-dependent manner. Pro-oxidant effects of lycopene have been observed at 
concentrations that are higher than physiological concentrations seen in vivo [55].  
3.2. Effects on Tumour Cell Proliferation and Growth 
Kotake-Nara et al. [57] examined 15 different carotenoids with regard to the potential of growth 
inhibition to the prostate cancer cell lines, PC3, DU145, and LNCaP. The authors found a significantly 
reduced cell viability after treatment with acyclic carotenoids at concentrations of 20 µmol/L 
Treatment at a concentration of 5 µmol/L resulted in an enhanced reduction of cell viability in 
particular for lycopene [57]. Another study, using a hexan extract of tomato paste resulted in a  
time- and dose-dependent decrease of cell proliferation of LNCaP cells, with maximal effects detected 
at a concentration of 5 µM lycopene. After 48 hours of incubation, growth inhibition reached 67%. 
However, as a tomato paste extract has been used instead of pure lycopene, it might be possible that 
the results have additionally been induced by other tomato components [58]. Ivanov et al. [59] 
compared two lycopene preparations, a 3% lycopene formulation from tomato powder (Lycopen™) 
and a tomato extract (LycoTrue™) to assess their potential to affect the proliferation of  
androgen-responsive LNCaP prostate cancer cells, as well as androgen-independent PC3 prostate 
cancer cells. They found a significant reduction in cell proliferation of LNCaP cells upon treatment 
with 1 µM or more Lycopen™. LycoTrue™ reduced cell numbers significantly at a concentration of 
0.5 µM after 48 h. Cell proliferation was not affected after exposure for 24 h or with only  
0.25 µM lycopene. Repeating the experiments with androgen-independent PC3 prostate cancer cells 
showed similar results. As the density of LNCaP cells has been found to be reduced after treatment for 
48 hours and no change has been found for PC3 cell density before and after treatment, a cytotoxic 
effect of lycopene to LNCaP cells and a simply cytostatic effect of lycopene on PC3 cells has been 
suggested [59]. Another study, using DU145 cells, found that lycopene induced a reduction of the 
proliferation rate at concentrations of 15 and 25 µM, but not at physiological concentrations below  
2 µM. To address if these effects have been due to oxidative products of lycopene, the study examined 
anti-proliferative effects of apo-12-lycopenal and apo-8-lycopenal (1–25 µM) on DU145 cells, thereby 
finding a significant reduction of proliferation only for apo-12-lycopenal. This finding indicates 
bioactivity for at least one of the lycopene metabolites [60]. In 2012, Yang et al. [61] showed that a 
lycopene induced activation of the PPARγ-LXRα-ABCA1 pathway was associated with  
anti-proliferative effects in LNCaP cells. The nuclear receptors, PPARγ and LXRα, build heterodimers 
with the retinoid X receptor. Activation of these heterodimers has been reported to be involved in 
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growth inhibition of prostate cancer cells [62,63]. Treatment of LNCaP cells for 24–96 h with 
concentrations up to 10 µM lycopene revealed anti-proliferative effects, as well as an increase in 
protein- and mRNA-expression of PPARγ, LXRα and ABCA1 [61]. Another study conducted by this 
group was extended to the use of the androgen independent cell lines, DU145 and PC3, resulting in a 
similar outcome [64]. They indicated a relationship between the ability of lycopene to reduce 
proliferation through the PPARγ-LXRα-ABCA1 pathway with an increase in cholesterol efflux in the 
tested cell lines. As an increased cholesterol metabolism has been reported to be involved in cancer 
progression, this finding might also be indicative for the antitumor potential of lycopene [61,64]. 
Contradictory to the studies discussed above, Burgess et al. [65] reported a failure of lycopene in 
inhibiting growth of DU145 cells at concentrations between 0.0001 and 10 µM and over a time of 72 h. 
The lycopene concentrations used in this study have been reported to lie within the physiological  
range [65]. Liu et al. [66] investigated the potential of lycopene and apo-10-lycopenal in preventing 
prostate cancer growth through epigenetic modifications. More precisely, they investigated a possible 
potential of the carotenoid to vary methylation patterns of DNA using LNCaP cells in both 
physiological and supra-physiological concentrations and examined the ability of lycopene or its 
metabolites to recover the expression of glutathione S-transferase P1 (GSTP1) through demethylation. 
However, they didn’t find any differences in DNA methylation of the promoter of GSTP1, thereby 
indicating that lycopene and its metabolites are not effective in demethylating DNA of LNCaP cells 
and, correspondingly, that they don’t affect cancer growth by inducing epigenetic modifications [66]. 
3.3. Effects on the Cell-Cycle 
The loss of the ability to regulate the cell-cycle is characteristic for cancer cells and results in 
uncontrollable proliferation. Processing cells through the first gap (G1) phase of the cell cycle is a step 
which is frequently disordered in cancer [67]. Lycopene has been investigated in different studies for 
its ability to mediate cell cycle arrest. 
Hwang et al. demonstrated that a tomato-paste extract induced arrest in both the G0/G1 phase and 
the G2/M phase of the cell-cycle of LNCaP cells via flow cytometry. First, effects have been detected 
after 24 h with treatment of 0.5 µM of the extract and increased with higher concentrations and 
expanded time periods. These results indeed showed the efficiency of the tomato paste extract to 
inhibit tumour cell proliferation at physiological concentrations. However, the authors did not analyse 
what components of the extract have been responsible for this finding [58]. Another study examined 
the influence of lycopene and one of its metabolites, apo-12-lycopenal, on the cell-cycle of DU145 
cells. The authors found a changed distribution pattern in the cell-cycle at concentrations 1–25 µM, 
with accumulation of cells in the G1 and G2/M-phase and reduction of cell numbers in the S-phase. 
Palozza et al. reported lycopene-induced cell-cycle arrest by describing molecular mechanisms [68]. 
After lycopene treatment, they revealed a reduced binding ability of NF-κB in LNCaP cells, which 
controls cell growth by influencing cell-cycle related proteins, and different apoptosis mediating 
proteins, like cyclin D1, p21, p27, p53, Bax or Bcl-2. A 24 hours exposure of lycopene resulted in a 
dose-dependent decrease of the G0/G1 phase-related protein, cyclin D1, and an increase in the cyclin 
kinase inhibitors, p53, p21 and p27. Measurement of cell-cycle distribution of LNCaP cells showed a 
clear increase in the number of cells in the G0/G1-phase and a corresponding decrease of the number of 
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cells in the S-phase [68]. Furthermore, this study revealed that lycopene interferes with the mevalonate 
pathway by reducing the expression of HMG-CoA reductase and by decreasing intracellular 
cholesterol levels upon treatment with concentrations ≥2.5 µM. Prenylation and translocation of Ras, 
which might play a role in redox regulation, has been found to be decreased after 24 h treatment of 
LNCaP cells. Subsequently, this might lead to NF-κB activation via modulation of redox-sensitive 
pathways and induce the above mentioned cell cycle arrest [68]. 
3.4. Potential to Induce Apoptosis  
Through the elimination of damaged, abnormal cells, the maintenance of a healthy, physiological 
organism is guaranteed. Cancer cells are, amongst others, characterized by the loss of the ability to 
undergo apoptosis [15]. 
Lycopene has been investigated for its capability to induce apoptosis in a couple of in vitro studies: 
Hwang et al. [58] detected apoptosis in the hormone sensitive prostate cancer cell line, LNCaP, after 
treatment with tomato paste extract for 24 and 48 h using an annexin V-FITC detection kit. Apoptosis 
has been detected predominantly in late stages, and most of the treated cells responded after 24 h of 
exposure to the tomato paste extract. Importantly, a significant increase in apoptosis has been reported 
after treatment with the physiologically relevant concentration of 1 µM [58]. Hantz et al. used pure 
lycopene instead of tomato extract to study its effect on apoptosis [69]. Alterations in mitochondrial 
function are a typical step in early apoptosis. These alterations involve enhanced permeability of  
the mitochondrial membrane to proteins, like cytochrome c, and disruption of the transmembrane 
potential [70]. Exposure of LNCaP cells to physiologically relevant concentrations of 0.3, 1.0, and  
3.0 µM lycopene induced a dose-dependent pro-apoptotic effect. Mitochondrial function was reduced 
at all concentrations tested, and a significant decrease of the mitochondrial transmembrane potential 
has been detected at concentrations of 1 and 3 µM lycopene. Furthermore, the authors found an 
increase of cytochrome c in the fraction of lycopene-treated cells as further evidence of apoptosis [69]. 
Ivanov et al. [59] reported a significant increase of apoptosis in LNCaP cells upon treatment with  
0.08 µM lycopene, reaching a steady state at 0.4 µM. However, concentrations of lycopene up to  
0.8 µM failed to cause apoptosis in PC3 prostate cancer cells. Unlike LNCaP cells, PC3 cells are not 
hormone-sensitive. In order to determine if signalling of the androgen receptor might be involved in 
apoptosis-inducing processes, androgen-responsive luciferase reporter assays have been used in this 
study. These assays revealed that lycopene has no impact on the signalling of these receptors and  
that the different outcome of the apoptosis studies might therefore not be dependent on androgen 
signalling [59]. Using concentrations of 20–60 µM lycopene, Kanagaraj et al. [71] detected apoptosis 
in PC3 cells. This finding was based on an increasing amount of insulin-like growth factor binding 
protein-3 and increased binding of annexin V and propidium iodide [71]. However, these 
concentrations are not attainable under physiological conditions. Teodoro et al. [72] found increased 
apoptosis rates in DU145 prostate cancer cells after incubation with 3 µM lycopene for 96 h. This dose 
comes close to those found in humans [72]. In a proteomic study using primary prostatic epithelial 
cells instead of a prostate cancer cell line, treated with 2 µmol/L of a lycopene beadlet formulation for 
48 h, Qiu et al. investigated lycopene-induced changes in the expression profile of proteins,  
thereby finding an upregulation of pro-apoptotic proteins (tyrosyl-tRNA synthetase, 40S ribosomal 
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protein S3 and pyruvate kinase isozyme M2), as well as a downregulation of anti-apoptotic  
proteins (chloride intracellular channel protein 1, heat shock 70 kDa protein 1A/B, HSPβ1, Rho  
GDP-dissociation inhibitor 1, translationally controlled tumour protein, lactoylglutathione lyase,  
78 kDa glucose-regulated protein and protein-kinase C inhibitor protein1) [51]. However, irrespective 
of changes in protein levels, there was no evidence of apoptosis in lycopene-treated primary prostatic 
epithelial cell cultures [51].  
3.5. Other Effects of Lycopene on Prostate Cancer Cells 
Several further in vitro studies have been undertaken trying to explain the mechanistic effects of 
lycopene on prostate cancer. A dose-dependent influence on androgen receptor element expression has 
been detected in LNCaP cells using a luciferase-reporter assay. It has been shown that lycopene 
inhibits the androgen receptor element, resulting in decreased PSA velocity, and may, therefore, 
provide an anti-hormonal potential. However, the effective end-concentration of 15 µmol/L has been 
supra-physiological [73]. 
Lycopene might also have an impact on invasion and migration of prostate cancer cells by reducing 
the expression of integrins, which are known to be involved in signalling processes regarding adhesion 
and invasion. Bureyko et al. [74] reported a decrease of α2β1-integrin-expression in 22Rv1-,  
LNCaP- and PC3- cells upon lycopene exposure. αvβ3 and αvβ5 integrins, usually highly expressed in 
more aggressive prostate cancer cell lines, have been found to be significantly decreased in PC3 cells 
after treatment with 0.01 µM lycopene. The lycopene concentrations used have been declared to lie 
within the physiological range [74].  
Additionally, lycopene has been shown to inhibit signalling of insulin-like growth factor-I (IGF-I) 
and, therefore, disrupts one pathway in the development of prostate cancer. Signalling of IGF-I and 
IGF-II via their receptor, IGF-IR, facilitates survival and proliferation of cancer cells using PI3K/Akt 
and MAPK pathways. Mobilization of Akt, which plays a key role in inducing IGF-I signals, may have 
a significant role in the development of an androgen-independent type of prostate-cancer [48]. After 
exposure of LNCaP cells to lycopene, a reduction of IGF-IR expression, as well as an Akt activation 
and an increase in the expression of insulin-like growth factor binding protein 2 (IGFBP2) has been 
shown. IGFBP2 is a binding protein for IGF-I, which has been shown to be highly expressed in 
LNCaP cells [59]. Another study conducted by Tang et al. [75] revealed that lycopene induced a more 
distinct inhibitory effect on the growth of DU145 prostate cancer cells, which exhibit a greater 
expression profile of IGF-IR, than on LNCaP, 22Rv1 or PC3 cells, which have a less pronounced  
IGF-IR level. Though lycopene accumulation in LNCaP cells has been detected to be more than four 
times higher than in DU145 cells, the growth inhibitory effect has been shown to be seven times less 
distinct. IGF-IR levels may play an important role in lycopene-mediated inhibition of cancer cell 
growth and are even more significant than the consideration of lycopene concentrations alone [75]. 
This study did not only show the involvement of IGF-IR in cell growth inhibition, but also, that the 
growth of DU-145, LNCaP, 22Rv1 and PC3 cells can further be inhibited by combining docetaxel and 
lycopene. Again, the greatest effect has been reported for DU-145 cells, exhibiting the highest levels of 
IGF-IR expression. Combining docetaxel therapy with lycopene may, therefore, especially be effective 
in cancer types expressing high levels of IGF-IR activity [75].  
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The above mentioned effects of lycopene are summarized in Figure 2. Taken all these effects and 
results together, a protective role of lycopene in prostate cancer can be embraced. However, the 
outcomes of the different studies are difficult to interpret and compare, as in vitro techniques show 
wide variations regarding cell lines, culture conditions, lycopene sources, concentrations and 
solubilizers of lycopene used [60].  
Figure 2. Potential effects of lycopene on prostate cancer cells. 
 
As lycopene is very lipophilic, co-solvents, like tetrahydrofuran (THF), foetal bovine serum (FBS) 
or preparations in special formulations, like water-dispersible beadlets, are necessary to solve and 
stabilize the molecule. Attempts to improve the availability include also the use of the emulsifiers, 
Tween 40 and Tween 80, as well as liposomal delivery systems [76–78]. However, every solubilizer 
has limitations and can influence, to some extent, the outcome of a study. THF, as well as compounds 
of liposomes, for example, have been shown to have toxic effects on some cell lines, whereas beadlets 
are composed of ingredients, like ascorbic acid and α-tocopherol, which are able to act as antioxidants 
by themselves. Tween and FBS have been shown to be less effective in stabilizing lycopene as 
compared to other solvents [15]. Results indicating no or low effects of lycopene are often conducted 
in a concentration range at the lower limit, whereas, on the other hand, some studies picture positive 
outcomes, although the lycopene concentrations used are supra-physiological. Furthermore, the 
interpretation of different studies is complicated, due to the high variation of lycopene formulations 
used. Spectra range from naturally derived extracted lycopene over synthetic lycopene formulations to 
tomato extracts, all containing different active compounds. It is therefore not surprising that cell 
culture studies investigating lycopene effects show great variations in their outcomes. 
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4. In Vivo Models 
The first in vivo effects of lycopene were reported by Lindberg and co-workers in 1959. The group 
showed that the ingestion of lycopene led to an increased survival of previously irradiated mice and to 
a lower incidence of radiation-induced peritoneal tumours [79,80]. Nevertheless, the first animal 
studies concerning the effects of lycopene on prostate cancer were not performed until the first studies 
had been published linking lycopene or tomato products with an antitumorigenic effect in prostate 
cancer patients. Though plenty of clinical studies have been performed so far, only a few preclinical  
in vivo studies have been published (Table 3). In August 2011, Ilic et al. identified 64 clinical  
studies [81], whereas at the same time, only 12 animal models had been published investigating the 
effects of lycopene on prostate cancer [75,82–90]. 
In the early 2000s, mainly syngeneic and chemically-induced models of prostate cancer have been 
used. Imaida et al. have been the first to test the chemopreventive efficacy of lycopene using a 
chemically-induced rat prostate cancer model (six-week-old male F344 rats) [85]. After carcinogen 
exposure with 3,2'-dimethyl-4-aminobiphenol for 20 weeks, lycopene purified from tomato extracts 
(99.9%, LycoRed™, Beer-Sheva, Israel) was incorporated in the basal diet (Oriental MF; Oriental 
Yeast co. Ltd, Tokyo, Japan) at a dosage of 15–45 ppm for 40 weeks. The authors found a significantly 
decreased incidence of prostatic intraepithelial neoplasia and carcinoma of the ventral prostate in 
animals treated with lycopene. However, these results have not been reproducible in subsequent 
experiments [85]. 
Guttenplan and co-workers examined the effects of dietary supplementation of a lycopene-rich 
tomato oleoresin on benzo[a]pyrene induced mutagenesis in six-week-old male lacZ mice [84]. The 
supplement consisted mainly of a 3.7% lycopene suspension (69 mM) in medium chain triglycerides 
(Cognis Corporation, LaGrange, IL, USA). The suspension contained different other natural 
carotenoids extracted from tomatoes (0.3% phytofluene, 0.44% Z-carotene, 0.47%  
2,6-cyclolycopene-1,5-diol and 1.2% β-carotene) and was incorporated into an AIN-76A diet at a 
concentration of 7 and 14 g/kg diet for eight weeks in parallel to carcinogen exposure.  
Carcinogen-induced tumorigenesis in prostates from the lycopene treated groups was decreased as 
compared to a control group without lycopene supplementation. However, the differences have not 
been significant [84].  
In 2003, Boileau et al. showed that supplementation with water-dispersible beadlets of synthetic 
lycopene (Hoffman-La Roche, Basel, Switzerland) at a concentration of 2.5 g of beadlets/kg of  
AIN-93G diet had no effects on the prostate cancer-specific survival of male Wistar rats.  
To induce carcinogenesis, they were previously treated with cyproterone, testosterone and  
N-methyl-N-nitrosourea [82]. However, the authors found that powder derived from heat-processed 
tomato paste (Armour/Del Monte Foods, San Francisco, CA, USA) incorporated into the diet at the 
same concentration as the synthetic lycopene was able to increase survival [82].  
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Table 3. Animal models investigating the effect of lycopene on prostate cancer. 
Author Year Strain Tumour model Lycopene formulation and source Outcome 
Imaida et al. [85] 2001 
6-week-old male 
F344 rats 
Chemically induced with  
3,2'-dimethyl-4-aminobiphenol 
Lycopene purified from tomato extracts 
(99.9%, LycoRed™, Beer-Sheva, Israel) 
Significantly decreased incidence 
of prostatic intraepithelial 
neoplasia and carcinoma of the 
ventral prostate 
Guttenplan et al. [84] 2001 
6-week-old male 
lacZ mice 
Chemically induced with 
benzo[a]pyrene 
Suspension of 3.7% Lycopene, 0.3% 
phytofluene, 0.44% Z-carotene, 0.47%  
2,6-cyclolycopene-1,5-diol and 1.2%  
β-carotene extracted from tomatoes  
(Cognis Corporation, LaGrange, IL, USA) 
Carcinogen-induced mutagenesis 
in prostates from the lycopene 
treated groups was decreased 
compared to a control group 
without lycopene supplementation 
Boileau et al. [82] 2003 
5-week-old male 
Wistar rats 
Chemically induced with 
cyproterone, testosterone and 
N-methyl-N-nitrosourea 
Beadlets of synthetic lycopene (Hoffman-La 
Roche, Basel, Switzerland) or powder 
derived from heat-processed tomato paste 
with skin and seeds (Armour/Del Monte 
Foods, San Francisco, CA, USA) 
Tomato powder, but not synthetic 
lycopene, was able to increase 
prostate cancer-specific survival 
iler et al. [87] 
2004, 
2005 
8–10-week-old 
male Copenhagen 
rats 
Orthotopic implantation of 
MatLyLu cells into the  
ventral prostate 
Beadlets of synthetic lycopene  
(Lycopene 5% TG, DSM Nutritional 
Products, Basel, Switzerland) 
MRI revealed a significant 
increase of necrotic area in 
tumours of lycopene treated 
animals. Anti-androgen and anti-
inflammatory effects on cancerous 
and healthy prostate tissue 
Venkateswaran et al. [89] 2004 
4–5-week-old 
transgenic male 
Lady mice 
Transgenic adenocarcinoma of 
the mouse prostate  
(TRAMP) model 
Mixture of antioxidants containing 800 IU 
vitamin E, 200 µg Selenium and 50 mg 
lycopene (no information about the supplier 
or the formulation was given) 
The mixture of micronutrients 
was able to inhibit prostate cancer 
development and to increase  
the disease-free survival  
of the animals. 
Tang et al. [91] 2005 
4–6-week-old 
male BALB/c 
nude mice 
Subcutaneous 
xenotransplantation of human 
prostate cancer cells (DU-145) 
along with Matrigel™ 
>95% pure lycopene with 6% lycopene 
oleoresin purified from tomato extracts (no 
information about the supplier was given) 
Decrease in tumour growth by 
55.6% and 75.8% in mice treated 
with 100 mg and 300 mg 
lycopene, respectively 
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Table 3. Cont. 
Author Year Strain Tumour model Lycopene formulation and source Outcome 
Canene-Adams et al. [83] 2007 
4-week-old male 
Copenhagen rats 
Subcutaneous implantation  
of minced Dunning R3327-H 
tumour tissue suspended  
in Matrigel™ 
Beadlets of synthetic lycopene (Lycopene 
5% TG, DSM Nutritional Products, Basel, 
Switzerland) or powder derived from 
tomatoes (Gilroy Foods, Gilroy, CA, USA) 
Synthetic lycopene insignificantly 
reduced tumour weight, whereas 
the reduction of tumour  
weight was significant for  
tomato powder. 
Konijeti et al. [92] 2010 
male transgenic 
TRAMP mice at 
weaning age 
TRAMP model 
Beadlets of synthetic lycopene (Lycopene 
10%, DSM Nutritional Products, Parsippany, 
NJ, USA) or tomato paste without skin and 
seeds (Campbell’s Soup Company, Camden, 
NJ, USA) 
Prostate cancer incidence was 
significantly decreased in the 
lycopene beadlet group, whereas 
the difference between the tomato 
paste group and the control group 
was not significant. 
Tang et al. [75] 2011 
NCR-nu/nu mice 
(no information 
about the age) 
Subcutaneous 
xenotransplantation of human 
prostate cancer cells (DU-145) 
Microencapsulated synthetic lycopene 
(LycoVit™ 10% CWD, BASF Corporation, 
Shreveport, LA, USA) alone or in 
combination with docetaxel i.p. 
Synthetic lycopene alone had no 
significant effects on tumour 
regression or survival. Docetaxel 
plus lycopene led to a significant 
tumour regression and increase in 
survival when compared to 
docetaxel alone. 
Yang et al. [90] 2011 
6–8-week-old 
male athymic 
nude mice 
Subcutaneous 
xenotransplantation of human 
prostate cancer cells (PC-3) 
Lycopene purified from tomato extracts 
(97%, Wako Pure Chemical Industries, 
Japan) or β-carotene 
Both lycopene and β-carotene 
significantly decreased tumour 
volume and weight. 
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Siler and co-workers used the MatLyLu-cell line to establish prostate tumours in 8–10-week-old 
male Copenhagen rats [87]. Supplementation of synthetic lycopene at a dosage of 200 ppm  
(lycopene 5% TG, DSM Nutritional Products, Basel, Switzerland) incorporated into a standard basal 
diet (Kliba #2019, Provimi Kliba AG, Kaiseraugst, Switzerland) for four weeks led to a significant 
increase of necrotic area within the tumours when compared to animals without lycopene 
supplementation. Hence, the authors suggested that lycopene can lead to a reduction of the prostatic 
tumour mass [87]. The same group found that synthetic lycopene induces anti-androgen and  
anti-inflammatory effects, both in cancerous and in healthy prostate tissue [88].  
Venkateswaran et al. have been the first to use a transgenic mouse model to investigate the effects 
of lycopene on prostate cancer [89]. They incorporated a mixture of antioxidants containing 800 IU 
vitamin E, 200 µg selenium and 50 mg lycopene into a standard diet (Purina Mills Test Diet, 
Richmond, Indiana, USA). After 25 weeks, they euthanized the animals and observed a four-fold 
reduction in the incidence of prostate cancer compared to untreated mice. Unfortunately, the authors 
did not provide any information about the formulations of the antioxidants used. The contribution of 
the different micronutrients was also not evaluated [89]. 
In 2005 Tang et al. [91] analysed the effect of natural lycopene on the growth of androgen-independent 
human DU145 prostate cancer cells after subcutaneous injection (1 × 10
7
 cells/100 µL Matrigel™) into 
the flanks of 4–6 week old male BALB/c nude mice. The lycopene-formulation used consisted of 
>95% pure lycopene with 6% lycopene oleoresin extracted from tomatoes. After tumour cell injection, 
the mice were gavaged five days per week with different dosages of lycopene (0, 10, 100 and  
300 mg/kg body weight) for eight weeks. The authors showed a decrease in tumour growth by 55.6% 
and 75.8% in mice treated with 100 mg and 300 mg lycopene. Mice injected with DU145 cells  
pre-treated with 20 µmol/L lycopene did not show any tumour formation after one month [91].  
Canene-Adams et al. implanted Dunning R3327-H tumour tissue with Matrigel™ (100 mg of 
tumour/mL Matrigel™) into the flanks of four-week-old male Copenhagen rats [83]. Synthetic lycopene 
beadlets (lycopene 5% TG, DSM Nutritional Products, Basel, Switzerland) or powder derived from 
tomatoes (Gilroy Foods, Gilroy, CA, USA) was incorporated into an AIN 93G-based diet, and 
supplementation started one month prior to tumour tissue transplantation. Tumour analysis at 18 weeks 
after tumour transplantation showed that 23 nmol or 224 nmol of synthetic lycopene beadlets per gram of 
diet insignificantly reduced tumour weights, whereas tomato powder at 13 nmol per gram of diet was able 
to significantly reduce the weight of the tumours as compared to the control groups [83]. In 2010, Konijeti 
et al. [92] used a TRAMP model to compare the effects of lycopene beadlets (lycopene 10%, DSM 
Nutritional Products, Parsippany, NJ, USA) and tomato paste (Campbell’s Soup Company, Camden, NJ, 
USA) on the incidence of prostate cancer. Both supplements were incorporated into the basal AIN 93 diet 
with 100 mg lycopene/kg diet since the age of weaning. In contrast to previously published studies [82,93], 
the authors found a significantly decreased incidence of prostate cancer in those animals treated with 
synthetic lycopene, but not in the animals treated with the tomato paste [92]. 
In 2011, Tang and co-workers [75] investigated the effect of synthetic lycopene and docetaxel on 
the survival and growth rate of xenografted tumours. DU145 prostate cancer cells were injected at a 
concentration of 1 × 10
6
 cells/100 µL PBS into the right flank of NCR-nu/nu nude mice. After the 
tumours reached a size of approximately 200 mm
3
, the mice were treated either with 15 mg/kg body 
weight of synthetic microencapsulated lycopene (LycoVit™ 10% CWD, BASF Corporation, 
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Shreveport, LA, USA) via gavage or with an intraperitoneal injection of docetaxel or with a 
combination of both. Docetaxel plus lycopene led to a significantly higher tumour regression and 
increase in survival when compared to docetaxel alone. The synthetic lycopene was able to enhance 
the antitumor capacity of docetaxel, even when it was given at a suboptimal dosing. However, 
lycopene alone had no effects on tumour regression or survival [75]. 
Yang and colleagues implanted human PC3 prostate cancer cells (1 × 10
7
 cells/100 µL PBS) into 
the flanks of 6–8-week-old athymic nude mice [90]. Subsequently, the mice were gavaged with 4 or 16 
mg/kg body weight of lycopene (97%, Wako Pure Chemical Industries, Japan; purified from tomatoes) 
or 16 mg/kg β-carotene suspended in corn oil twice a day for seven weeks. The authors showed that 
both lycopene and β-carotene were able to significantly decrease tumour volume and weight when 
compared to a control group without supplementation. The lycopene effect has been shown to be 
dosage-dependent [90]. 
The results of previously published animal studies are in large parts inconsistent. This is mainly due 
to the heterogeneity of the lycopene formulations and animal models used. As reviewed in Table 3, 
lycopene formulations vary from synthetic lycopene to purified naturally derived lycopene and  
non-purified tomato powder or mixtures of different substances. Several other critical issues need to be 
considered, such as the dosage, form and bioavailability of the active component and the timing of the 
treatment. Nevertheless, the preclinical data strongly suggests an antitumorigenic activity of lycopene 
and its different formulations, either alone or in combination with other substances.  
5. Lycopene for the Prevention and Therapy of Prostate Cancer: Clinical Evidence 
Lycopene, with its abundant availability, low costs and lack of side effects, would be a suitable 
antitumorigenic drug, but there is still no clear clinical evidence whether to support or refute its use for 
the prevention or therapy of prostate cancer [94]. In the literature, there are plenty of epidemiological 
studies [95–98] analysing the effects of tomato-based products on prostate cancer, but research that 
specifically investigates lycopene supplementation is limited. Most of the published studies have a low 
level of evidence, and there is only a limited number of published randomized clinical trials [99]. 
A Cochrane review published in 2011 by Ilic and co-workers [81] investigated the capability of 
lycopene for the prevention of prostate cancer and identified only three randomized controlled trials 
with a total of 154 participants with prostatic intraepithelial neoplasia or benign prostate hyperplasia 
using lycopene as the intervention. Two [100,101] of these three studies [100–102] posed a high risk 
of bias, especially in blinding of participants and personnel [81]. Only one of these three studies reported 
the incidence of prostate cancer. Although a decreased prostate cancer incidence has been found for the 
intervention group, the difference to the control group was statistically not significant [101]. 
In 2011, van Breemen et al. [103] published the results of another randomized controlled clinical 
trial including 105 men with a PSA level greater than 4 ng/mL and abnormal digital rectal examination 
or ultrasonography. Twenty-one days before, prostate biopsy patients were either randomized to the 
lycopene or the control group. Effects on PSA level or incidence of prostate carcinoma have not been 
reported in this study. Lycopene concentration in plasma and prostate tissue from the patients who 
received lycopene has been significantly higher than in the control group. However, no significant 
differences in molecular markers of oxidative stress could be found [103] (Table 4). 
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Table 4. Randomized controlled clinical trials analysing the effects of lycopene on the prevention of prostate cancer. 
Author Year Patients Follow-up Lycopene formulation and source Outcome 
Mohanty et al. [101] 2005 
40 patients with high-grade 
intraepithelial neoplasia (intervention 
group: 20, control group: 20) 
2 years 
4 mg lycopene (Lyc-O-Mato™, LycoRed Natural 
Products Industries, Ltd., Beer-Sheva, Israel) twice a 
day for one year; Lyc-O-Mato™ is a tomato-oleoresin 
extracted from tomatoes, which contains a high amount 
of lycopene as well as other natural tomato 
phytonutrients, such as tocopherols, phytoene, 
phytofluene, β-carotene, phospholipids and 
phytosterols. 
The incidence of prostate cancer was 10% in 
the intervention and 30% in the control group. 
PSA levels in the lycopene group decreased 
from a mean level of 6.07 to 3.5 ng/mL and 
increased in the control group from 6.55 to 
8.06 ng/mL. Accordingly, the serum 
lycopene increased in the treatment group 
from 360 to 680 ng/mL and decreased in the 
control group from 378 to 180 ng/mL. 
Bunker et al. [100] 2007 
80 patients with high-grade 
intraepithelial neoplasia, atypical foci or 
more than one non-cancerous biopsy 
(intervention group: 40, control group: 
40; both groups were treated with a 
multivitamin mixture during the study) 
4 months 
15 mg lycopene (Lyc-O-Mato™, LycoRed Natural 
Products Industries, Ltd., Beer-Sheva, Israel) twice a 
day for the duration of the follow-up 
No difference in PSA levels between groups 
were reported, neither at one month, nor four 
months after initiation of the intervention. 
Serum lycopene levels doubled in the 
intervention group. Incidence of prostate 
cancer was not reported. 
Schwarz et al. [102] 2008 
40 patients with histologically proven 
benign prostate hyperplasia (intervention 
group: 20, control group: 20) 
6 months 
15 mg microencapsulated synthetic lycopene 
(LycoVit™ 10%, BASF, Ludwigshafen, Germany) 
once a day for the duration of the follow-up 
Significant reduction of PSA levels in the 
intervention group, but not in the control 
group (p < 0.05). Accordingly, serum 
lycopene was increased in the intervention, 
but not in the control group (p < 0.0001). 
Prostate enlargement could be detected in the 
control group via trans-urethral ultrasonography 
(p < 0.05) and digital rectal examination  
(p < 0.01), whereas the prostate did not 
enlarge in the intervention group. Incidence 
of prostate cancer was not reported. 
Van Breemen et al. [103] 2011 
131 patients scheduled for prostate cancer 
biopsy as a result of elevated PSA levels 
and an abnormal digital rectal examination 
or ultrasonography (intervention group: 69, 
control group 62) 
21 days 
15 mg lycopene (Lyc-O-Mato™, LycoRed Natural 
Products Industries, Ltd., Beer-Sheva, Israel) twice a 
day for 21 days 
Significant increase of lycopene levels in the 
serum (p < 0.0001) and prostate tissue  
(p = 0.005) in the intervention group. No 
significant changes in the DNA oxidation 
product 8-oxo-desoxyguanosine and the lipid 
peroxidation product, malondialdehyde, in 
prostate tissue or plasma. No significant 
difference in prostate cancer incidence. 
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Though there is a considerable interest in lycopene as a therapeutic agent, only few high quality 
studies have been reported analysing its effect on prostate cancer. In 2012, Ilic and Misso [99] 
published a systematic review in which they identified only four randomized controlled clinical studies 
that tested lycopene as a therapeutic agent for prostate cancer (Table 5) [104–107]. One of the studies 
posed a high risk of bias [105]. 
Table 5. Randomized controlled clinical trials analysing the therapeutic effects of lycopene 
in prostate cancer. 
Author Year Patients Follow-up 
Lycopene formulation and 
source 
Outcome 
Kucuk et al. [106] 2001 
26 patients with 
clinically diagnosed 
prostate cancer prior to 
scheduled prostatectomy 
(intervention group: 15, 
control group: 11) 
3 weeks 
15 mg lycopene (Lyc-O-Mato™, 
LycoRed Natural Products 
Industries, Ltd., Beer-Sheva, 
Israel) once a day for 3 weeks 
PSA serum levels decreased 
by 18% in the intervention 
group and increased by 14% in 
the control group (p = 0.25). 
73% of the intervention and 
18% of the control group had 
microscopically free resection 
margins (p = 0.02). 84% of 
the intervention and 45% of 
the control group had tumour 
volumes >4 mL (p = 0.222). 
Ansari et Gupta [104] 2003 
54 patients with prostate 
cancer metastases and 
orchidectomy 
(intervention group: 27, 
control group: 27) 
24–28 
months 
2 mg lycopene twice a day (no 
information about the supplier  
or the formulation) 
After 2 years, the PSA serum 
levels were significantly lower 
in the intervention group  
(p < 0.001). The survival rate 
measured by the Kaplan-Meier 
method was significantly higher 
in the intervention group  
(p < 0.001). There was a 
significantly improvement in 
urinary peak flow rate in the 
lycopene group (p = 0.04) 
Vaishampayan et al. [107] 2007 
71 patients with 
histologically proven 
prostate cancer and 
rising serum PSA levels 
following local therapy 
or during hormone 
therapy (intervention 
group: 38, control 
group: 33) 
5.5–6 
months 
15 mg lycopene (Lyc-O-Mato™, 
LycoRed Natural Products 
Industries, Ltd., Beer-Sheva, 
Israel) twice a day for 6 months in 
the intervention group. The control 
group was treated with the same 
dosage of lycopene and soy 
isoflavone 40 mg twice a day for 
5.5 months. 
No decline in serum PSA level 
in either group. However, in 
both therapeutic arms, there was 
a significant decline in the rate 
of PSA increase from  
pre-therapy to  
post-therapy. 
Grainger et al. [105] 2008 
41 patients with 
recurrent prostate cancer 
(intervention group: 20, 
control group: 21) 
8 weeks 
The diet in the intervention group 
consisted of tomato and/or tomato 
products containing at least 25 mg 
lycopene per day given for 4 weeks. 
The control group was treated with 
soy protein. After 4 weeks, both 
groups were treated with lycopene 
25 mg and soy protein for another  
4 weeks. 
Serum lycopene levels increased 
significantly in both groups after 
8 weeks of dietary intervention. 
There was no statistically 
significant difference in PSA 
serum levels between the 
groups. 
6. Conclusions  
While in vitro studies predominantly demonstrated the chemopreventive effects of lycopene on 
prostate cancer cells, its effectiveness in vivo has still to be proven. Attempts to recapitulate the 
antitumorigenic activity of lycopene in animal models have been in some parts highly significant and 
showed interesting data, suggesting the potential of lycopene to reduce tumour growth rate and to 
increase the survival of the animals. However, the results have mainly been inconsistent [108]. 
Stringent animal models and a clear definition of the lycopene-preparations used are strongly 
recommended before results can be transferred to the clinical setting. Nevertheless, the use of lycopene 
in the clinic still rests on findings derived from randomized controlled clinical trials. Recent systematic 
Int. J. Mol. Sci. 2013, 14 14640 
 
 
reviews could show that lycopene is able to decrease the serum PSA-levels in patients with prostate 
hyperplasia or cancer, demonstrating its effect on proliferating prostate cells [81,99]. In the future, 
newly designed randomized controlled clinical trials might contribute to a better understanding of 
lycopene effects on prostate cancer patients. 
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